{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"Ergebnisqualität bei Darmkrebs: Identifikation von Unterschieden und Maßnahmen zur flächendeckenden Qualitätsentwicklung","eudractNumber":null,"id":11661,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-01T14:29:16+01:00","shortTitle":"EDIUM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ergebnisqualität bei Darmkrebs: Identifikation von Unterschieden und Maßnahmen zur flächendeckenden Qualitätsentwicklung","eudractNumber":null,"id":5299,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-12-01T09:00:32+01:00","shortTitle":"EDIUM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ziel dieser multizentrischen, randomisierten, doppelblinden, aktiv-komparator-kontrollierten, adaptiven Phase-2/3-Studie ist die Entwicklung einer neuartigen Kombinationsimmuntherapie, EIK1001 + Pembrolizumab, für die Behandlung des Melanoms","eudractNumber":"2024-512659-19-00","id":11739,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"}],"nctNumber":"NCT06697301","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-11-26T11:42:59+01:00","shortTitle":"EIK1001-006","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/ bortezomib/ dexamethasone (I-VRD) followd by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followd standard of care intensification followed by maintenance therapy with lenalidomide and isatuximab

Short title: Expression-linked and R-Iss-Adapted Stratification for first line therapy in multiple myeloma patients (ELIAS)
","eudractNumber":"2020-005102-26","id":9532,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05665140","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-07-01T12:46:18+02:00","shortTitle":"ELIAS","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"

Mantelzell-Register, Einschluss aller Linien","eudractNumber":null,"id":7531,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-11-01T12:47:28+01:00","shortTitle":"EMCL Register","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued
Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
","eudractNumber":"2024-519827-16-00","id":11504,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06932562","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-11-10T09:57:13+01:00","shortTitle":"EMN 39","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase II Trial of Teclistamab in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis","eudractNumber":"2024-519191-90-00","id":11509,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06649695","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-07-25T13:24:44+02:00","shortTitle":"EMN 40","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Machbarkeit von Ganzkörper Elektro-Muskel-Stimulation (WB-EMS) bei Patienten, die sich einer allogenen Stammzelltransplantation unterziehen werden

DRKS00035358
","eudractNumber":null,"id":10185,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-12-02T12:37:39+01:00","shortTitle":"EMpower - Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Deutsches Nebennierenkarzinom Register -->
seit 17.06.2011:
Register und Biobank des Europäischen Netzwerks für Nebennierentumoren ENS@T (European Network for the Study of Adrenal Tumours)
","eudractNumber":null,"id":94,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2003-01-01T09:48:37+01:00","shortTitle":"ENSAT-Register","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"

 Surgery as\nneeded versus surgery on principle in patients with postneoadjuvant\nclinical complete tumor response of esophageal\ncancer - ESORES-Trial 

DRKS00022801

","eudractNumber":null,"id":10294,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-10-15T09:16:00+02:00","shortTitle":"ESORES","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}